CSI Market
Sign In | Register

Rapport Therapeutics Inc (RAPP) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access RAPP quarterly Cash Flow →
Tracking cash flow results across Rapport Therapeutics Inc to helps illustrate how Dec 31 2025's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024)
Operating Activities
Income-111.48
Depreciation & amortization1.02
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation18.86
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Change In Fair Value Of Preferred Stock Tranche Right Liability-
Operating Lease Right Of Use Asset Amortization Expense2.03
Increase Decrease In Operating Lease Liabilities-0.49
Non- Cash Loss On Sale Of Property And Equipment-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable2.22
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities6.17
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-3.60
Other Working Capital-0.79
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.40
Discontinued operations0.00
Net Cash flow from Operating Activities-87.47
Investing Activities
Capital Expenditures-0.62
Sale of Capital Items0.00
Proceeds from Sale of Short-term Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments-186.86
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-187.47
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.35
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.02
Proceeds From Initial Public Offering And Concurrent Private Placement Net Of Underwriter Discounts And Commissions And Deferred Offering Costs-
Settlement Of Series A Preferred Stock Tranche Right Liability-
Deferred Offering Costs-
Conversion Of Stock Amount Converted-
Noncash Or Part Noncash Acquisition Fixed Assets Acquired0.02
Payments For Repurchase Of Unvested Restricted Common Stock0.00
Proceeds From Underwritten Public Offering Net Of Underwriter Discounts And Commissions And Deferred Offering Costs269.44
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities270.79
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-88.09
Total Cash Flow-4.16
4 historic quarters locked

Sign in to unlock the full Rapport Therapeutics Inc cash flow history.

Sign In Create Free Account

About Rapport Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-099360

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License